ReviewClinical reviews in allergy & immunology2012
Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature.
Review in Clinical reviews in allergy & immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review.Frontiers in medicine · 2025Pooled it
- Guideline
- Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2015Trial
- Antimitochondrial Antibody Measurements in the Diagnosis of Antimitochondrial Antibody-negative and Alkaline Phosphatase-positive Primary Biliary Cholangitis: An Update and Review.Journal of clinical and translational hepatology · 2026Review
- The Role of Laboratory Markers in Primary Biliary Cholangitis: A Clinical Review and a Case Report.Biomedicines · 2026Review
- Identifying the clinical signature of anti-centromere antibody-positive Sjögren's syndrome: a machine learning-based analysis of a multicenter cohort.Frontiers in immunology · 2026Article
- [Clinical characteristics and risk factors for disease progression in patients with anti-gp210 antibody-positive primary biliary cholangitis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.Journal of clinical and translational hepatology · 2025Article
- Role of autoantibodies in the clinical management of primary biliary cholangitis.World journal of gastroenterology · 2023Review
- Research experimental design for the construction and identification of the pGEX-BCKD-E4A recombinant point-mutant plasmid.PloS one · 2023Article
- Optimization of Laboratory Diagnostics of Primary Biliary Cholangitis: When Solid-Phase Assays and Immunofluorescence Combine.Journal of clinical medicine · 2022Article
- Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases.Journal of translational autoimmunity · 2022Article
- Clinical impact of antibodies to Sp100 on a bacterial infection in patients with primary biliary cholangitis.Journal of clinical laboratory analysis · 2021Article
- Analysis of Autoantibodies against Promyelocytic Leukemia Nuclear Body Components and Biochemical Parameters in Sera of Patients with Primary Biliary Cholangitis.Diagnostics (Basel, Switzerland) · 2021Article
- Investigation and analysis of HEp 2 indirect immunofluorescence titers and patterns in various liver diseases.Clinical rheumatology · 2020Article
- Article
- Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.PloS one · 2020Article
- [Is autoimmune cholangitis-anti-mitochondrial antibody-negative primary biliary cholangitis still an independent disease?]Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019Review
- Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis.Gastroenterology research and practice · 2019Article
- Biomarkers for primary biliary cholangitis: current perspectives.Hepatic medicine : evidence and research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum anti-mitochondrial antibodies (AMA) are the serological hallmark of primary biliary cirrhosis (PBC), yet up to 15% of PBC sera are AMA negative at routine indirect immunofluorescence (IIF) while being referred to as "probable" cases. The diagnostic role of PBC-specific antinuclear antibodies (ANA) remains to be determined. We will report herein data on the accuracy of new laboratory tools for AMA and PBC-specific ANA in a large series of PBC sera that were AMA-negative at IIF. We will also provide a discussion of the history and current status of AMA detection methods. We included IIF AMA-negative PBC sera (n=100) and sera from patients with other chronic liver diseases (n=104) that had been independently tested for IIF AMA and ANA; sera were blindly tested with an ELISA PBC screening test including two ANA (gp210, sp100) and a triple (pMIT3) AMA recombinant antigens. Among IIF AMA-negative sera, 43/100 (43%) manifested reactivity using the PBC screening test. The same test was positive for 6/104 (5.8%) control sera. IIF AMA-negative/PBC screen-positive sera reacted against pMIT3 (11/43), gp210 (8/43), Sp100 (17/43), both pMIT3 and gp210 (1/43), or both pMIT3 and Sp100 (6/43). Concordance rates between the ANA pattern on HEp-2 cells and specific Sp100 and gp210 ELISA results in AMA-negative subjects were 92% for nuclear dots and Sp100 and 99% for nuclear rim and gp210. Our data confirm the hypothesis that a substantial part of IIF AMA-negative (formerly coined "probable") PBC cases manifest disease-specific autoantibodies when tested using newly available tools and thus overcome the previously suggested diagnostic classification. As suggested by the recent literature, we are convinced that the proportion of AMA-negative PBC cases will be significantly minimized by the use of new laboratory methods and recombinant antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.